Drugs for chronic obstructive pulmonary disease
- PMID: 28246430
- PMCID: PMC5313246
- DOI: 10.18773/austprescr.2017.003
Drugs for chronic obstructive pulmonary disease
Keywords: COPD (chronic obstructive pulmonary disease); antimuscarinics; beta agonists; corticosteroids.
Conflict of interest statement
Christine Jenkins contributes to many educational programs and symposia for government, non-government organisations and the pharmaceutical industry. She is a member of national and international advisory boards and steering committees for AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim and Novartis.
References
-
- Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators . Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010;11:122. 10.1186/1465-9921-11-122 - DOI - PMC - PubMed
-
- Yang IA, Dabscheck E, George J, Jenkins S, McDonald CF, McDonald V, et al. The COPD-X plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease 2016. Version 2.46, June 2016. Milton, Queensland: Lung Foundation Australia and the Thoracic Society of Australia and New Zealand; 2016.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources